UCB's Global Corporate Website

This section is intended for media and financial analysts

Transparency notification FMR LLC

Brussels (Belgium), 18 March 2022 – 20:05 (CET) – Regulated information 

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from FMR LLC. (having its registered office at 245 Summer Street, Boston, Massachusetts, 02210, U.S.A.), on 16 March 2022. 

FMR LLC., has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA has increased and it has crossed the 5% threshold, on 14 March 2022.

On 14 March 2022, FMR LLC. (taking into account the holding of its affiliates) owned 9 770 956 UCB shares with voting rights, representing 5.02% of the total number of shares issued by the company (194 505 658), versus 4.98% (9 690 661 UCB shares) in the previous notification dated 31 January 2022.

2.  Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights. 
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement

  • Date on which the threshold is crossed: 14 March 2022. 
  • Threshold crossed (in %): 5%.
  • Denominator: 194 505 658.
  • Notified details:

  • Chain of controlled undertakings through which the holding is effectively held:

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

For further information, contact UCB: 

Investor Relations
Antje Witte 
T +32 2 559 94 14

Corporate Communications
Laurent Schots 
T+32 2 559 92 64

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news


Asset Download

Stay up-to-date on the latest news and information from UCB